With additional competitors on key generics expected to challenge Hikma in 2022, as well as the looming threat of increased overall pricing pressures in the US, the company’s CEO Siggi Olafsson remains confident that the company can weather the storm.
One way in which Hikma is ensuring that it maximizes its potential is through investment
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?